🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Kicked off ASCO #AsiaPacific #RegionalCouncil meeting in #Kuching #Sarawak 🇲🇾 w/ dedicated council members representing our region and #ASCOStaff. Happy to #vett & #deliver specific initiatives which will benefit #oncology landscape in our region. Roselle De Guzman Melvin LK CHUA | FRCR, PhD, FASCO

Our ASCO #AsiaPacific #RegionalCouncil meeting in #Kuching #Sarawak. Led by the amazingly energetic Melvin LK CHUA | FRCR, PhD, FASCO, I am glad to be part of this group helping shape #ASCO’s engagement with members and planning specific #initiatives in our region. @drkiwikate Diah Martina

Prof Jacky Lam sharing at the CUHK Medicine Department of Clinical Oncology Academic Meeting on liquid biopsy for early cancer detection #oncology

#ESMOVirtualPlenary: And straight after the first abstract session tomorrow (9/5), remain connected to discover more promising results on #GIST. 📢 A randomised study of 6 vs 3 years of adjuvant imatinib in pts w/ localised GIST at high risk of relapse. ow.ly/rKAa50Rza70

Congrats Jean-Yves Blay & colleagues of #FrenchSarcomaGroup for completing study of #6vs3years of #adjuvant #imatinib 💊i n pts w/ #highrisk #GISTs. Presented at ESMO - Eur. Oncology AACR #virtualplenary over last #2days with #specific discussions from #APAC #discussants as well!

Truly honored to have been invited to speak on EGFR-mut NSCLC at the National Cancer Center in Singapore by Daniel Tan and his incredible team. Grateful for the opportunity to share insights and collaborate on such an important topic Daniel Tan SingHealth Pankaj Kumar Panda

📢 T-28 days to our 6th CUHK Medicine #CUHKSarcoma Masterclass in #hongkong 🇭🇰! We are looking forward to welcoming #international and #local faculties to our annual event. Congrats to 8 overseas attendees who have been #awarded #travelgrants to #present and #attend this year's

📢Announcement: Join us at our 1st #APODDCForum2024 where we discuss about the Regulatory Harmonisation for Oncology Clinical Trials & Therapeutics Registration in the APAC Region📷 Sign up now via lnkd.in/gDPsHNib!📧 More details on our LinkedIn Page!

Thanks Daniel Goldstein MD for coming all the way from 🇮🇱 to 🇭🇰 to share insights and experiences in #pharmacoeconomics. Organised by #ProfVivianLee and colleagues of CUHK Pharmacy Very engaged workshop together with stakeholders from #academia, #industry, #patientsrepresentatives and

Thank you Jean-Yves Blay for your excellent talk at the xxx bokep🇬🇧 - EORTC workshop #RareCancers You last slides summarized it so well

Thank you superstar Herbert Loong, MBBS, FASCO for being a keynote speaker NZSOncology Timely discussions on accessibility/ cost savings for #PrecisionOncology Need personalise a model for 🇳🇿 too! APODDC Health New Zealand | Te Whatu Ora Te Aho o Te Kahu | Cancer Control Agency NZ

Thanks Prof. Chris Jackson @drkiwikate Annie Wong 黃毅敏 Laird Cameron #DaisyMak (who needs to get on Twitter! 😆) & all my other 🇳🇿 #oncology friends NZSOncology for your invitation & hospitality. Amazing talks & discussions throughout the conference. Perfect forum to build collaborations.

Phase 2 Study: Trametinib Treatment of Epithelioid Hemangioendothelioma. bit.ly/40pDRBc

It's ok at #CTOS2024 to drag me to your poster to pitch your science for Clinical Cancer Research, it the most inspiring thing i get to do!!

Delighted to share our review paper on ADCs in NSCLC with AGA is out! Very timely given the anticipated data readouts this year. Such an honour to be a part of this awesome team, special thanks to Giannis Mountzios and Jordi Remon for leading this 🙌🏻

It's pleasure coauthoring this Cancer Cell commentary with 2 talented drug development fellows #gregoire marret and #mercedes herrera Princess Margaret Cancer Centre - "Turning the Kaleidoscope: Innovations shaping the future of clinical trials design" authors.elsevier.com/a/1kljp5TA51lC…

🔥 Journal of Clinical Oncology 🆙 ✅LIBRETTO-001 final: Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer 🎯mOS 47.6 (pretreated pts), not reached (treatment-naïve) 👥 Oliver Gautschi #LCSM OncoAlert

Wonderful crew of ESMO - Eur. Oncology #ESMORarecancer25 #YOCasesDiscussion session! Definitely not-so-young oncologists including #myself are also welcome. Great cases discussed and thanks everyone for contributing to lively discussions. Pawel Sobczuk Liz Connolly Roberta Sanfilippo

Newly published ESMO recommendations provide roadmap for the implementation of molecular tumour boards in clinical practice. Discover the key focus areas to optimise #PrecisionOncology Read via #ESMODailyReporter: ow.ly/mexL50VvtUM Ben Westphalen Annals of Oncology

Safety of tarlatamab with 6-8h outpatient vs 48-h inpatient monitoring during C1: DeLLphi-300 ph1 substudy in ESMO Open. Outpatient monitoring feasible, same CRS rate, most managed w/o hospitalization/ER visit. Anticipate&monitor AEs in educated pts is🔑. esmoopen.com/article/S2059-…